This site is intended for healthcare professionals
Optimising anti-TNF treatment using biosimilars

Decision Making

Read time: 10 mins
In this Section

Studies show that when patients have an active involvement in treatment decisions and are more educated about their treatment they will elect for more conservative treatment options.2 Patients who adhere to their treatments are three times more likely to achieve desired outcomes, such as improved quality of life and better functional capacity, than nonadherent patients.3 

When HCPs and patients engage in SDM there is a greater likelihood of adherence for patients, often with the added bonus of reduced health care costs.3 Health care costs attributable to nonadherence annually in the United States are estimated to be $100–$300 billion per year.4

Register free for full access to medthority.com

Click here to register now

The increasing numbers of anti-TNF biosimilars available on the market represent increasing treatment options for patients and potentially improved rates of remission. 

HCPs are starting to re-evaluate the need of applying exit strategies for anti-TNF therapy with the reduced costs of these treatments, following the advent of biosimilars.

Register free for full access to medthority.com

Click here to register now
Welcome:
Sign in/Register
Updates in your area
of interest
Articles your peers
are looking at
Bookmarks
saved
Days to your
next event

References

  1. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient. Med Decis Making. 2015 Jan; 35(1): 114–131. doi: 10.1177/0272989X14551638
  2. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: A model for clinical practice. J Gen Intern Med. 2012;27(10):1361-1367. doi:10.1007/s11606-012-2077-6
  3. Anghel L-A, Farcaş AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. 2018. doi:10.2147/PPA.S165101
  4. Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: A systematic literature review. Patient Prefer Adherence. 2018;12:1483-1503. doi:10.2147/PPA.S167508
  5. Schuler CL, Dodds C, Hommel KA, Ittenbach RF, Denson LA, Lipstein EA. Shared decision making in IBD: A novel approach to trial consent and timing. Contemp Clin Trials Commun. 2019;16. doi:10.1016/j.conctc.2019.100447
  6. Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053-1060. doi:10.1001/jamapediatrics.2015.1982
  7. Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: Treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417-1427. doi:10.1093/ibd/izz001
  8. Razanskaite V, Bettey M, Downey L, et al. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. J Crohns Colitis. 2017;11(6):690-696. doi:10.1093/ecco-jcc/jjw216
  9. Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. 393(10182):1699-1707, APRIL 27, 2019 DOI:https://doi.org/10.1016/S0140-6736(18)32196-2
  10. Gecse KB, Cumming F, D'Haens G. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients’ concerns? Expert Review of Gastroenterology & Hepatology, 13:2, 143-155, DOI: https://doi.org/10.1080/17474124.2019.1553617
  11. Peyrin-Biroulet L, Danese S, Cummings F, et al. Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach. Expert Rev Gastroenterol Hepatol. 2019;13(8):731-738. doi:10.1080/17474124.2019.1645595
  12. Scherlinger, M., Langlois, E., Germain, V., & Schaeverbeke, T. (2018). Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Seminars in Arthritis and Rheumatism. doi:10.1016/j.semarthrit.2018.07.005
  13. Innala L, Berglin E, Möller B, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: A prospective study. Arthritis Res Ther. 2014;16(2). doi:10.1186/ar4540
  14. Lofland JH, Johnson PT, Ingham MP, Rosemas SC, White JC, Ellis L. Shared decision-making for biologic treatment of autoimmune disease: Influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adherence. 2017;11:947-958. doi:10.2147/PPA.S133222
  15. Bronckers IMGJ, van Geel MJ, van de Kerkhof PCM, de Jong EMGJ, Seyger MMB. A cross-sectional study in young adults with psoriasis: potential determining factors in quality of life, life course and work productivity. J Dermatolog Treat. 2019;30(3):208-215. doi:10.1080/09546634.2018.1506077
  16. Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: Real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4). doi:10.1136/bmjopen-2018-027535
  17. Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches tomoderate to severe psoriasis. Int J Mol Sci. 2017;18(11). doi:10.3390/ijms18112427
  18. Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J. Persistence of treatment with biologics for patients with psoriasis: a real‐world analysis of 16 545 biologic‐naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019;180(1):86-93. doi:10.1111/bjd.16809
  19. Biosimilar adalimumab is a test of shared decision-making in the NHS | Crohn’s & Colitis UK. https://www.crohnsandcolitis.org.uk/healthcare-professionals/healthcare-professionals-blog/biosimilar-adalimumab-is-a-test-of-shared-decision-making-in-the-nhs. Accessed January 17, 2020.
  20. Renzi C, Di Pietro C, Gisondi P, et al. Insufficient Knowledge Among Psoriasis Patients Can Represent a Barrier to Participation in Decision-making. Acta Derm Venereol. 2006;86(6):528-534. doi:10.2340/00015555-0145
  21. Larsen MH, Hagen KB, Krogstad AL, Wahl AK. Shared Decision Making in Psoriasis: A Systematic Review of Quantitative and Qualitative Studies. Am J Clin Dermatol. 2019 Feb;20(1):13-29. doi: 10.1007/s40257-018-0390-5.
  22. Doherty G, Katsanos KH, Burisch J, et al. European Crohn’s and colitis organisation topical review on treatment withdrawal [’exit strategies’] in inflammatory bowel disease. J Crohn’s Colitis. 2018;12(1):17-31. doi:10.1093/ecco-jcc/jjx101
  23. Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci. 2018;19(8). doi:10.3390/ijms19082244
  24. Gisbert JP, Marin AC, Chaparro M. Am J Gastroenterol. 2016 May;111(5):632-47. doi: 10.1038/ajg.2016.54. Epub 2016 Mar 22.
  25. Ryan T, Coffey L, Mullen A, Leyden J, MacMathuna P. P557 Sustained remission in inflammatory bowel disease patients after discontinuing infliximab; the ongoing reluctance to stop biologics. J Crohn’s Colitis. 2019;13(Supplement_1):S392-S392. doi:10.1093/ecco-jcc/jjy222.681
  26. Studies Investigate Drug Survival, Discontinuation of Biologics in IBD. https://www.centerforbiosimilars.com/conferences/ecco-2019/studies-investigate-drug-survival-discontinuation-of-biologics-in-ibd. Accessed January 17, 2020.
  27. Doherty J, Buckley M, Cullen G, et al. P405 Sustainability of biologic therapies is less in UC than CD patients independent of prior biologic experience. J Crohn’s Colitis. 2019;13(Supplement_1):S311-S311. doi:10.1093/ecco-jcc/jjy222.529
  28. Mangoni AA, Al Okaily F, Almoallim H, Al Rashidi S, Mohammed RHA, Barbary A. Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature. BMC Rheumatol. 2019;3(1). doi:10.1186/s41927-019-0058-7
  29. Galvao TF, Zimmerman IR, da Mota LM, Silva MT, Pereira MG. Clin Rheumatol. 2016 Jul;35(7):1659-68. doi: 10.1007/s10067-016-3285-y. Epub 2016 Apr 23.
  30. Chatzidionysiou K, Sfikakis PP. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: Review of randomised controlled trials could point towards a paradigm shift. RMD Open. 2019;5(2). doi:10.1136/rmdopen-2019-000993
  31. Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases. 2018 Aug 16; 6(8): 161–166.
  32. Costa L, Perricone C, Chimenti MS, et al. Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. Drugs R D. 2017;17(4):509-522. doi:10.1007/s40268-017-0215-7
  33. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11(2):R52. doi: 10.1186/ar2670. Epub 2009 Apr 8.
  34. Fabbroni M, Cantarini L, Caso F, et al. Drug retention rates and treatment discontinuation among anti-TNF- α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm. 2014;2014. doi:10.1155/2014/862969
  35. Saougou I, Markatseli TE, Papagoras C, Voulgari P V., Alamanos Y, Drosos AA. Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study. Semin Arthritis Rheum. 2011;40(5):398-406. doi:10.1016/j.semarthrit.2010.07.004